HIMS Stock Rebounds 6% Despite Five More States Joining FTC Suit; Rating Remains WAIT

What happened

Hims & Hers shares climbed 6% on November 11, 2026, even as five additional states joined the FTC lawsuit alleging deceptive privacy, billing, and cancellation practices, while key drug suppliers Eli Lilly and Novo Nordisk declined to participate in the rally. The bounce likely reflects short covering and bargain hunting after a sharp selloff, rather than any fundamental improvement, since the legal overhang has widened and the weight-loss transition still pressures margins. The master report's WAIT rating stands because Q2 2026 gross margin fell to 64% and free cash flow turned negative, and the company has not yet shown that branded GLP-1 economics can restore profitability. Management's Q3 revenue guidance of $880–900M suggests demand remains strong, but the absence of supplier participation in the rally signals no relief on drug procurement costs. Investors should treat the 6% move as noise until Q3 results confirm margin recovery and legal accruals stop rising.

Implication

The 6% rise is a tactical bounce, not a signal to buy, because the core bear case—margin compression from branded GLP-1s and FTC remedies that could impair customer acquisition—remains intact. With five more states joining the suit, the probability of operational restrictions or higher legal costs has risen, while suppliers sitting out the rally suggests no near-term improvement in drug economics. The stock is trading near $30.9, still above the attractive entry of $24 but below the trim level of $37, so no action is warranted until Q3 2026 earnings provide evidence on gross margin and adjusted EBITDA margin. If Q3 results show gross margin above 66% and legal accruals at or below $62.5M, the thesis improves; otherwise, the downside case of $22 comes into play. For now, holding or waiting for better entry is prudent.

Thesis delta

No change to the WAIT rating or conviction level. The FTC litigation has expanded with five additional states, increasing regulatory risk, but there is no new operating data to alter the fundamental thesis. The key catalysts remain Q3 2026 gross margin recovery above 66% and stabilization of legal contingencies.